Skip to main content
SpringerLink
Log in

Antidiabetic Agents

  • Living reference work entry
  • First Online:
Critical Care Toxicology

  • 279 Accesses

Abstract

Antidiabetic agents include insulin and nine classes of oral drugs:

This is an update of the chapter originally written by Christopher H. Linden in the first edition of this text.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 1487–517.

    Google Scholar 

  2. Sims EAH, Calles-Escandon J. Insulin, glucagon, and oral hypoglycemics in the treatment of diabetes mellitus. In: Munson PL, Mueller RA, Breese GR, editors. Principles of pharmacology: basic concepts and clinical applications, rev reprint. New York: Chapman & Hall; 1996. p. 697–723.

    Google Scholar 

  3. McEvoy GK, Litvak K, Welsh OH, et al., editors. AHFS drug information. Bethesda: American Society of Health-System Pharmacists; 2000.

    Google Scholar 

  4. Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol. 2014;8(6):1071–3.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ferner RE, Chaplin S. The relationship between the pharmacokinetic and the pharmacodynamic effects of oral hypoglycemic drugs. Clin Pharmacokinet. 1987;12:397–401.

    Article  Google Scholar 

  6. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res. 1995;27:263–6.

    Article  CAS  PubMed  Google Scholar 

  7. Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Expert Opin Invest Drugs. 2000;9:885–98.

    Article  CAS  Google Scholar 

  8. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–9.

    Article  CAS  PubMed  Google Scholar 

  9. Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014;63(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  10. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1–19.

    Article  Google Scholar 

  11. Ceriello A, Sportiello L, Rafaniello C, Rossi F. DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opin Drug Saf. 2014;13(S1):57–68.

    Article  CAS  Google Scholar 

  12. White JR. Dipeptidyl peptidase-IV inhibitors: pharmacological profile and clinical use. Clin Diabet. 2008;26(2):53–7.

    Article  Google Scholar 

  13. Traina AN, Kane MP. Primer on pramlintide, an amylin analog. Diabetes Educ. 2011;37(3):426–31.

    Article  PubMed  Google Scholar 

  14. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53:S233–8.

    Article  CAS  PubMed  Google Scholar 

  15. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013;53(6):601–10.

    Article  CAS  PubMed  Google Scholar 

  16. Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris A-G, Kasichayanula S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2014;38:1–8.

    Google Scholar 

  17. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Juurlink DN, Roberts DM. The enigma of metformin-associated lactic acidosis. Clin Toxicol (Phila). 2014;52(2):85–7.

    Article  CAS  Google Scholar 

  20. Horikoshi H, Hashimoto T, Fujiwara T. Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control. Prog Drug Res. 2000;54:191–212.

    Article  CAS  PubMed  Google Scholar 

  21. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61–71.

    Article  CAS  PubMed  Google Scholar 

  22. Cohen V, Teperikidis E, Jellinek SP, Rose J. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia. Clin Toxicol (Phila). 2008;46(4):346–7.

    Article  CAS  Google Scholar 

  23. Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther. 2005;27(2):210–5.

    Article  CAS  PubMed  Google Scholar 

  24. Nakayama S, Hirose T, Watada H, Tanaka Y, Kawamori R. Hypoglycemia following a nateglinide overdose in a suicide attempt. Diabetes Care. 2005;28(1):225.

    Article  Google Scholar 

  25. Russell JL, Casavant MJ, Spiller HA, Mercurio-Zappala M. Clinical effects of exposure to DPP-4 inhibitors as reported to the National Poison Data System. J Med Toxicol. 2014;10(2):152–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204–12.

    Article  CAS  PubMed  Google Scholar 

  27. Lee NJ, Norris SL, Thakurta S. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus. Ann Fam Med. 2010;8(6):542–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2012;44(4):375–93.

    Article  CAS  PubMed  Google Scholar 

  29. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173–8.

    Article  CAS  PubMed  Google Scholar 

  30. Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabet Metab Case Rep. 2015. doi:10.1530/EDM-15-0042.

    Google Scholar 

  31. Safety Announcement. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA Drug Saf Commun. 2015.

    Google Scholar 

  32. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015.

    Google Scholar 

  33. Spiller HA. Management of antidiabetic agents in overdose. Drug Saf. 1998;19:411–24.

    Article  CAS  PubMed  Google Scholar 

  34. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163–83.

    CAS  PubMed  Google Scholar 

  35. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism: mechanisms and management. Drug Saf. 1999;15:135–57.

    Article  Google Scholar 

  36. Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am. 1999;28:555–77.

    Article  CAS  PubMed  Google Scholar 

  37. Shilo S, Berezovsky S, Friedlander Y, et al. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc. 1998;46:978–82.

    Article  CAS  PubMed  Google Scholar 

  38. Klonoff DC, Barrett BJ, Nolte MS, et al. Hypoglycemia following inadvertent and factitious sulfonylurea overdosages. Diabetes Care. 1995;18:563–7.

    Article  CAS  PubMed  Google Scholar 

  39. Owen L, Ellis M, Shield J. Deliberate sulphonylurea poisoning mimicking hyperinsulinaemia of infancy. Arch Dis Child. 2000;82:392–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Roberge RJ, Martin TG, Delbridge TR. Intentional massive insulin overdose: recognition and management. Ann Emerg Med. 1993;22:228–34.

    Article  CAS  PubMed  Google Scholar 

  41. Haymond MW. Hypoglycemia in infants and children. Endocrinol Metab Clin North Am. 1989;18:211–52.

    CAS  PubMed  Google Scholar 

  42. Moore DF, Wood DF, Volans GN. Features, prevention, and management of acute overdose due to antidiabetic drugs. Drug Saf. 1993;9:218–29.

    Article  CAS  PubMed  Google Scholar 

  43. Field JB. Hypoglycemia: definition, clinical presentations, classification, and laboratory tests. Endocrinol Metab Clin North Am. 1989;18:27–43.

    CAS  PubMed  Google Scholar 

  44. Service FJ. Hypoglycemia. Med Clin North Am. 1995;79:1–8.

    Article  CAS  PubMed  Google Scholar 

  45. Cryer PE. Hypoglycemia: pathophysiology, diagnosis, and treatment. Oxford: Oxford University Press; 1997.

    Google Scholar 

  46. Odeh M, Oliven A, Bassan H. Transient atrial fibrillation precipitated by hypoglycemia. Ann Emerg Med. 1990;19:565–7.

    Article  CAS  PubMed  Google Scholar 

  47. Chelliah YR. Ventricular arrhythmias associated with hypoglycaemia. Anaesth Intensive Care. 2000;28:698–700.

    CAS  PubMed  Google Scholar 

  48. Marques JL, George E, Peacey SR, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med. 1997;14:648–54.

    Article  CAS  PubMed  Google Scholar 

  49. Lindstrom T, Jorfeldt L, Tegler L, et al. Hypoglycaemia and cardiac arrhythmias in patients with type 2 diabetes mellitus. Diabet Med. 1992;9:536–41.

    Article  CAS  PubMed  Google Scholar 

  50. Shimada R, Nakashima T, Nunoi K, et al. Arrhythmia during insulin-induced hypoglycemia in a diabetic patient. Arch Intern Med. 1984;144:1068–9.

    Article  CAS  PubMed  Google Scholar 

  51. Weston PJ, Gill GV. Is undetected autonomic dysfunction responsible for sudden death in type 1 diabetes mellitus? The ‘dead in bed’ syndrome revisited. Diabet Med. 1999;16:626–31.

    Article  CAS  PubMed  Google Scholar 

  52. Pollock G, Brady Jr WJ, Hargarten S, et al. Hypoglycemia manifested by sinus bradycardia: a report of three cases. Ann Emerg Med. 1996;3:700–7.

    CAS  Google Scholar 

  53. Kramer DC, Fleischer FS, Marx GF. Fetal bradycardia resulting from maternal hypoglycemia: a report of two cases. J Reprod Med. 1995;40:394–6.

    CAS  PubMed  Google Scholar 

  54. Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–80.

    Article  CAS  PubMed  Google Scholar 

  55. Kedes LH, Field JB. Hypothermia: a clue to the diagnosis of hypoglycemia. N Engl J Med. 1964;271:785–7.

    Article  CAS  PubMed  Google Scholar 

  56. Passias TC, Meneilly GS, Mekjavic IB. Effect of hypoglycemia on thermoregulatory responses. J Appl Physiol. 1996;80:1021–32.

    CAS  PubMed  Google Scholar 

  57. Matsumura M, Nakashima A, Tofuku Y. Electrolyte disorders following massive insulin overdose in a patient with type 2 diabetes. Intern Med. 2000;39:55–7.

    Article  CAS  PubMed  Google Scholar 

  58. Arem R, Zoghbi W. Insulin overdose in eight patients: insulin pharmacokinetics and review of the literature. Medicine. 1985;64:323–32.

    Article  CAS  PubMed  Google Scholar 

  59. Plum S, Posner JB. The diagnosis of stupor and coma. 3rd ed. Philadelphia: FA Davis; 1980. p. 219–22.

    Google Scholar 

  60. Luber SD, Brady WJ, Brand A, et al. Acute hypoglycemia masquerading as head trauma: a report of four cases. Am J Emerg Med. 1996;14:543–7.

    Article  CAS  PubMed  Google Scholar 

  61. Gold AE, Marshall SM. Cortical blindness and cerebral infarction associated with severe hypoglycemia. Diabetes Care. 1997;14:309–15.

    CAS  Google Scholar 

  62. Spiller HA, Schroeder S, Ching DSY. Hemiparesis and altered mental status in a child after glyburide ingestion. J Emerg Med. 1998;16:433–5.

    Article  CAS  PubMed  Google Scholar 

  63. Stapczynski JS, Haskell RJ. Duration of hypoglycemia and need for intravenous glucose following intentional overdoses of insulin. Ann Emerg Med. 1984;13:505–11.

    Article  CAS  PubMed  Google Scholar 

  64. Samuels MH, Eckel RH. Massive insulin overdose: detailed studies of free insulin levels and glucose requirements. Clin Toxicol. 1989;27:157–68.

    CAS  Google Scholar 

  65. Shibutani Y, Ogawa C. Suicidal insulin overdose in a type 1 diabetic patient: relationship of serum insulin concentrations to the duration of hypoglycemia. J Diabetes Complications. 2000;14:60–2.

    Article  CAS  PubMed  Google Scholar 

  66. Quadrani DA, Spiller HA, Widder P. Five year retrospective evaluation of sulfonylurea ingestion in children. J Toxicol Clin Toxicol. 1996;34:267–70.

    Article  CAS  PubMed  Google Scholar 

  67. Spiller HA, Villalobos D, Krenzelok EP, et al. Prospective multicenter study of sulfonylurea ingestion in children. J Pediatr. 1997;131:141–6.

    Article  CAS  PubMed  Google Scholar 

  68. Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy. Arch Intern Med. 1991;151:1859–62.

    Article  CAS  PubMed  Google Scholar 

  69. Cienchanowski K, Borowiak KS, Potocka BA, et al. Chlorpropamide toxicity with survival despite 27-day hypoglycemia. Clin Toxicol. 1999;37:869–71.

    Google Scholar 

  70. McLelland J. Recovery from metformin overdose. Diabet Med. 1985;2:410–1.

    Article  CAS  PubMed  Google Scholar 

  71. Heaney D, Majid A, Junor B. Bicarbonate haemodialysis as a treatment of metformin overdose. Nephrol Dial Transplant. 1997;12:1046–7.

    Article  CAS  PubMed  Google Scholar 

  72. Brady WJ, Carter CT. Metformin overdose. Am J Emerg Med. 1997;15:107–8.

    Article  CAS  PubMed  Google Scholar 

  73. Teale KF, Devine A, Stewart H, Harper NJ. The management of metformin overdose. Anaesthesia. 1998;53:698–701.

    Article  CAS  PubMed  Google Scholar 

  74. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20:377–84.

    Article  CAS  PubMed  Google Scholar 

  75. Gan SC, Barr J, Arieff AI, et al. Biguanide-associated lactic acidosis: case report and review of the literature. Arch Intern Med. 1992;152:2333–6.

    Article  CAS  PubMed  Google Scholar 

  76. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. Diabetologia. 1978;14:75–87.

    Article  CAS  PubMed  Google Scholar 

  77. Jurovich MR, Wooldridge JD, Force RW. Metformin-associated nonketotic metabolic acidosis. Ann Pharmacother. 1997;31:53–5.

    CAS  PubMed  Google Scholar 

  78. Vecchio S, Giampreti A, Petrolini VM, Lonati D, Protti A, Papa P, et al. Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol. 2014;52(2):129–35.

    Google Scholar 

  79. Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir. 1938;3:237–45.

    Google Scholar 

  80. Glatstein M, Scolnik D, Bentur Y. Octreotide for the treatment of sulfonylurea poisoning. Clin Toxicol. 2012;50(9):795–804.

    Article  CAS  Google Scholar 

  81. Merimee TJ, Tyson JE. Stabilization of plasma glucose during fasting: normal variations in two separate studies. N Engl J Med. 1974;291:1275–8.

    Article  CAS  PubMed  Google Scholar 

  82. Stanley CA. Hyperinsulinism in infants and children. Pediatr Clin North Am. 1997;44:363–74.

    Article  CAS  PubMed  Google Scholar 

  83. Lebowitz MR, Blumenthal SA. The molar ratio of insulin to C peptide: an aid to the diagnosis of hypoglycemia due to surreptitious (or inadvertent) insulin administration. Arch Intern Med. 1993;153:650–5.

    Article  CAS  PubMed  Google Scholar 

  84. Kim MR, Sheeler LR, Mansharamani N, et al. Insulin antibodies and hypoglycemia in diabetic patients. Endocrine. 1997;6:285–91.

    Article  CAS  PubMed  Google Scholar 

  85. Hampton SM, Beyzavi K, Teale D, et al. A direct assay for proinsulin and its applications in hypoglycemia. Clin Endocrinol. 1988;29:9–16.

    Article  CAS  Google Scholar 

  86. Matchinsky FM, Sweet IR. Annotated questions and answers about glucose metabolism and insulin secretion of β-cells. Diabetes Rev. 1996;4:130–44.

    Google Scholar 

  87. Kumar D, Mehtalia S, Miller L. Diagnostic use of glucagon-induced insulin response: studies in patients with insulinoma or other hypoglycemia conditions. Ann Intern Med. 1974;80:697–701.

    Article  CAS  PubMed  Google Scholar 

  88. Feingold DN, Stanley CA, Baker L. Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. J Pediatr. 1980;96:257–9.

    Article  Google Scholar 

  89. Slama G, Traynard P, Desplanque N, et al. The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med. 1990;150(3):589–93.

    Article  CAS  PubMed  Google Scholar 

  90. Bayly GR, Ferner RE. Persistent insulin secretion after insulin overdose in a non-diabetic patient. Lancet. 1993;341:370.

    Article  CAS  PubMed  Google Scholar 

  91. Adler PM. Serum glucose changes after administration of 50 % dextrose solution: pre- and in-hospital calculations. Am J Emerg Med. 1986;4:504–6.

    Article  CAS  PubMed  Google Scholar 

  92. Balentine JR, Gaeta TJ, Kessler D, et al. Effect of 50 milliliters of 50% dextrose in water administration on the blood sugar of euglycemic volunteers. Acad Emerg Med. 1998;5:691–4.

    Article  CAS  PubMed  Google Scholar 

  93. Vukmir RB, Paris PM, Yealy DM. Glucagon: prehospital therapy for hypoglycemia. Ann Emerg Med. 1991;20(4):375–9.

    Article  CAS  PubMed  Google Scholar 

  94. Patrick AW, Collier A, Hepburn DA, Steedman DJ, Clarke BF, Robertson C. Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Arch Emerg Med. 1990;7(2):73–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Thoma ME, Glauser J, Genuth S. Persistent hypoglycemia and hyperinsulinemia: caution in using glucagon. Am J Emerg Med. 1996;14:99–101.

    Article  CAS  PubMed  Google Scholar 

  96. Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol. 2015;87:496–504.

    Google Scholar 

  97. Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76:752–6.

    CAS  PubMed  Google Scholar 

  98. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36:133–8.

    Article  CAS  PubMed  Google Scholar 

  99. Kannisto H, Neuvonen PJ. Adsorption of sulfonylureas onto activated charcoal in vitro. J Pharm Sci. 1984;73:253–5.

    Article  CAS  PubMed  Google Scholar 

  100. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position paper: single-dose activated charcoal. Clin Toxicol. 2005;43(2):61–87.

    Article  Google Scholar 

  101. Campbell IW, Ratcliffe JG. Suicidal insulin overdose managed by excision of insulin injection site. BMJ (Clin Res Ed). 1982;285:408–9.

    Article  CAS  Google Scholar 

  102. McIntyre AS, Woolf VJ, Burnham WR. Local excision of subcutaneous fat in the management of insulin overdose. Br J Surg. 1986;73:538.

    Article  CAS  PubMed  Google Scholar 

  103. Neuvonen PJ, Karkkainen S. Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther. 1983;33:386–93.

    Article  CAS  PubMed  Google Scholar 

  104. Proudfoot AT, Krenzelok EP, Vale JA. Position paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42(1):1–26.

    Article  CAS  PubMed  Google Scholar 

  105. Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, et al. Extracorporeal treatment for metformin poisoning. Crit Care Med. 2015;43:1716–30.

    Article  PubMed  Google Scholar 

  106. Lalau JD, Andrejak M, Moriniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27:285–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emergency Medicine, Regions Hospital, Minneapolis, MN, USA

    Jenna M. LeRoy

  2. Medical School, University of Minnesota, Minneapolis, MN, USA

    Samuel J. Stellpflug

Authors
  1. Jenna M. LeRoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel J. Stellpflug
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jenna M. LeRoy or Samuel J. Stellpflug .

Editor information

Editors and Affiliations

  1. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Jeffrey Brent

  2. Office of New Drugs Drug Evaluation and Research, FDA, Silver Spring, Maryland, USA

    Keith Burkhart

  3. Clinical Toxicology, St Thomas' Hospital, London, United Kingdom

    Paul Dargan

  4. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Benjamin Hatten

  5. Med & Toxicological Intensive Care Unit, Lariboisière Hospital Paris-Diderot University, Paris, France

    Bruno Megarbane

  6. University of Colorado School of Medicine, Toxicology Associates, Denver, Colorado, USA

    Robert Palmer

Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition

Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition

  1. I

    Evidence obtained from at least one properly randomized controlled trial.

  2. II-1

    Evidence obtained from well-designed controlled trials without randomization.

  3. II-2

    Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.

  4. II-3

    Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.

  5. III

    Opinions of respected authorities, based on clinical experience, descriptive studies and case reports, or reports of expert committees.

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

LeRoy, J.M., Stellpflug, S.J. (2016). Antidiabetic Agents. In: Brent, J., Burkhart, K., Dargan, P., Hatten, B., Megarbane, B., Palmer, R. (eds) Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-20790-2_112-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20790-2_112-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-20790-2

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation